Amsbio has announced a second-generation PARP in vivo Pharmacodynamic Assay that accurately measures net poly (ADP-ribose) (PAR) levels in cellular extracts.
The assay has been used to document differences in PAR levels in human tumour lysates from a variety of tissues, organs and xenografts.
Poly-ADP-ribose polymerase (PARP) is a protein involved in a number of cellular processes including catalysing the NAD-dependent addition of PAR onto itself and other adjacent nuclear proteins.
PARP-1 is widely regarded as a promising target for the development of drugs useful in various regimes of cancer therapy, inflammation, ischemia and neurodegeneration.
More recently, the discovery that breast cancers deficient in homologous recombination are sensitive to non-toxic PARP inhibitors has resulted in efforts by numerous pharmaceutical companies to develop PARP-1 specific drugs.
Amsbio's PARP in vivo Pharmacodynamic Assay uses a validated sample-processing regime and a chemiluminescent, sandwich Elisa format, with pre-coated 96-stripwell plates.
The assay reports PAR level with high signal-to-noise ratio, sensitivity of 2pg/ml and a linear dynamic range to 1,000pg/ml.
The PARP in vivo Pharmacodynamic Assay offers a tool that provides evidence of drug action on molecular targets and generates baseline values that may be used to stratify patient response to therapy.
